PharVision Advisers’s Boston Scientific BSX Stock Holding History

PharVision Advisers’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,244	Closed	-$595K	–	172
2025 Q4	$595K	Buy	6,244 +766	+14%	+$75.1K	0.3%	16
2025 Q3	$535K	Buy	5,478 +3,105	+131%	+$322K	0.3%	18
2025 Q2	$255K	Sell	2,373 -1,436	-38%	-$145K	0.37%	129
2025 Q1	$384K	Buy	+3,809	New	+$384K	0.53%	41

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PharVision Advisers's BSX Position: Q1 2026 in Review

PharVision Advisers sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 6,244 shares — an estimated $595K sold.

PharVision Advisers first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $595K in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

PharVision Advisers reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 6,244 Boston Scientific shares in Q1 2026, an estimated $595K.
PharVision Advisers first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
PharVision Advisers's Boston Scientific position peaked at $595K in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.